180. Keegan D, Bowen RC, Blackshaw S, et al., A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol 1991;6:117-124. 181. Keller MB, Trivedi MH, Thase ME, et al., The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 2007;62:1371-1379. 182. Khajavi D, Farokhnia M, Modabbernia A, et al., Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:1428-1433. 183. Khan A, Bose A, Alexopoulos GS, et al., Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007;27:481-492. 184. Kiev A and Feiger A, A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997;58:146-152. 185. Kim JE, Yoon SJ, Kim J, et al., Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract 2011;65:323-329. 186. Klysner R, Bent-Hansen J, Hansen HL, et al., Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;181:29-35. 187. Kranzler HR, Mueller T, Cornelius J, et al., Sertraline treatment of co-occurring alcohol dependence and depression. J Clin Psychopharmacol 2006;26:13-20. 188. Kyle CJ, Petersen HE and KF, Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998;8:147-153.
180. Keegan D, Bowen RC, Blackshaw S, et al., A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol 1991;6:117-124. 181. Keller MB, Trivedi MH, Thase ME, et al., The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 2007;62:1371-1379. 182. Khajavi D, Farokhnia M, Modabbernia A, et al., Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:1428-1433. 183. Khan A, Bose A, Alexopoulos GS, et al., Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007;27:481-492. 184. Kiev A and Feiger A, A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997;58:146-152. 185. Kim JE, Yoon SJ, Kim J, et al., Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract 2011;65:323-329. 186. Klysner R, Bent-Hansen J, Hansen HL, et al., Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;181:29-35. 187. Kranzler HR, Mueller T, Cornelius J, et al., Sertraline treatment of co-occurring alcohol dependence and depression. J Clin Psychopharmacol 2006;26:13-20. 188. Kyle CJ, Petersen HE and KF, Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998;8:147-153.